 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
62 News |  |
- | Trivastal (piribedil) / Servier
Preclinical, Journal: A novel arylpiperazine derivative (LQFM181) protects against neurotoxicity induced by 3- nitropropionic acid in in vitro and in vivo models. (Pubmed Central) - May 19, 2024
In the pursuit of novel antioxidant therapies for the prevention and treatment of neurodegenerative diseases, three new arylpiperazine derivatives (LQFM181, LQFM276, and LQFM277) were synthesized through a molecular hybridization approach involving piribedil and butylated hydroxytoluene lead compounds...Interestingly, using the same in vivo model, LQFM181 also reduced locomotor behavior and memory dysfunction through its ability to decrease cholinesterase activity. Consequently, LQFM181 emerges as a promising candidate for further investigation into its neuroprotective potential, positioning it as a new therapeutic agent for neuroprotection.
- | Trivastal (piribedil) / Servier
Journal: Postural stability and walking in Parkinson's disease (Pubmed Central) - Nov 27, 2023
The article discusses the existing problems according to the latest literature data, a review on the treatment and rehabilitation of postural instability. Special attention in the article is paid to dopamine receptor agonists - namely, piribedil, prescribed for the correction of these disorders.
- | Trivastal (piribedil) / Servier
Retrospective data, Journal: Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study. (Pubmed Central) - Nov 20, 2023
Special attention in the article is paid to dopamine receptor agonists - namely, piribedil, prescribed for the correction of these disorders. Carbidopa/levodopa or levodopa/benserazide might exhibit better clinical improvement with less medical cost, while piribedil presented less clinical improvement but a higher risk of headache/dizziness, gastrointestinal, and neuropsychiatric symptoms.
- || Trivastal (piribedil) / Servier, pirepemat (IRL752) / IRLAB Therap
Review, Journal: A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders. (Pubmed Central) - Jul 29, 2023
Pharmacological interventions for apathy in aging neurocognitive disorders are complex and under-investigated. The continuation of systematic research efforts and the provision of individualized treatment for patients suffering from these disorders is vital.
- || Trivastal (piribedil) / Servier
Retrospective data, Review: Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis. (Pubmed Central) - Jul 3, 2023
In addition, the incidence of adverse reaction of ropinirole IR was relatively high (nausea: 0.678; somnolence: 0.752; dizziness: 0.758; fatigue: 0.890). In this systematic review and network meta-analysis of six NEDAs, piribedil exhibited better efficacy, especially as monotherapy, and ropinirole IR was associated with a higher incidence of adverse events in patients with early PD.
- | Trivastal (piribedil) / Servier
Journal: Motor and autonomic disorders influence on pain syndrome of patients with Parkinson's disease of the I-III H&Y stages (Pubmed Central) - Apr 25, 2023
In this systematic review and network meta-analysis of six NEDAs, piribedil exhibited better efficacy, especially as monotherapy, and ropinirole IR was associated with a higher incidence of adverse events in patients with early PD. The piribedil inclusion contributes to the reduction of pain syndrome, regardless is it used in monotherapy or in conjunction with levodopa preparations.
- | Trivastal (piribedil) / Servier
Journal: Upper gastrointestinal tract dysfunction and its correction by dopamine agonists for patients with Parkinson's disease of I-III stage (Pubmed Central) - Nov 29, 2022
The piribedil inclusion contributes to the reduction of pain syndrome, regardless is it used in monotherapy or in conjunction with levodopa preparations. The inclusion of piribedil (150-250 mg/day) in the 6-months therapy reduces the dysfunction of the upper gastrointestinal tract (by 61 and 74% of the initial level of dysphagia and sialorrhea, respectively) regardless the drug use in monotherapy or in complex therapy with levodopa.
- | Odomzo (sonidegib) / Sun Pharma, Trivastal (piribedil) / Servier, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Journal: A General C-N Cross-Coupling to Synthesize Heteroaryl Amines Using a Palladacyclic N-Heterocyclic Carbene Precatalyst. (Pubmed Central) - Nov 22, 2022
Applying this precatalyst enabled a general protocol for Pd-catalyzed C-N cross-coupling reactions of challenging five- or six-membered ring heteroaryl chlorides and various heterocyclic amines. The desired aminated products, including commercial pharmaceuticals or key intermediates such as piribedil, cyprodinil, BRAF inhibitor, tripelennamine, 517-β-hydroxysteroid dehydrogenase inhibitor, brexpiprazole, and sonidegib, were achieved in good to excellent yields (>61 examples, ≤99% yields).
- || Trivastal (piribedil) / Servier, Haruropi tape (ropinirole transdermal) / Hisamitsu, Kyowa Kirin
Retrospective data, Review, Journal: Efficacy and Safety of Non-Ergot Dopamine-receptor Agonists as an Adjunct to Levodopa in Advanced Parkinson's Disease: A Network Meta-Analysis. (Pubmed Central) - Nov 19, 2022
In comprehensive consideration of better symptomatic management, ropinirole PR may be a better choice than other NEDAs in advanced PD. Six NEDAs showed different profiles of AEs.
- Trivastal (piribedil) / Servier
Social behavioral profiling by unsupervised deep learning reveals a stimulative effect of dopamine D3 agonists on zebrafish sociality (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_10636;
The D3 agonists pramipexole, piribedil, and 7-hydroxy-DPAT-HBr rescued social deficits in a valproic acid-induced zebrafish autism model. The ZeChat platform provides a promising approach for dissecting the pharmacology of social behavior and discovering novel social-modulatory compounds.
- | Trivastal (piribedil) / Servier
Preclinical, Journal: Piribedil loaded thermo-responsive nasal in situ gelling system for enhanced delivery to the brain: formulation optimization, physical characterization, and in vitro and in vivo evaluation. (Pubmed Central) - Apr 8, 2022
Overall, it can be concluded that intranasal delivery of PBD is advantageous when compared to the currently practiced oral therapy. Graphical abstract.
- | Trivastal (piribedil) / Servier
Journal: Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability. (Pubmed Central) - Mar 30, 2022
Further, PBD-Susp showed limited direct nose to brain uptake with DTP values less than 0, while the optimized PBD-LCNs showed DTP value of 56% indicating efficient direct nose to brain uptake. Overall, the development of nanoformulations significantly improved the direct nose to brain uptake of PBD.
- rasagiline / Generic mfg.
[VIRTUAL] Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_1239;
This case warrants further investigation on the effect of CSAI on the oral cavity. It also illustrates the necessity of multidisciplinary follow-up in PD patients, as underreporting is a major limitation to drug safety surveillance.
- || Trivastal (piribedil) / Servier
PK/PD data, Journal: Design, Optimization and Pharmacokinetic Evaluation of Piribedil Loaded Solid Lipid Nanoparticles Dispersed in Nasal In Situ Gelling System for Effective Management of Parkinson's Disease. (Pubmed Central) - Sep 9, 2021
In vivo pharmacokinetic studies showed that PBD-SLN-ISG increased the PBD (AUC) by about 4-folds and reduced the (C) by 2.3-folds when compared to plain intranasal suspension of PBD (PBD-Susp). Further, PBD-Susp showed limited direct nose to brain uptake with direct transport percentage (DTP) values less than 0, while the optimized PBD-SLN-ISG showed DTP value of 27% indicating efficient direct nose to brain uptake.
- | Trivastal (piribedil) / Servier
Journal: Othello syndrome in Parkinson's disease: A diagnostic emergency of an underestimated condition. (Pubmed Central) - Jul 31, 2021
At the time of the management of the OS, three patients had already divorced their spouse. It is imperative for clinicians to know this underestimated syndrome in order to identify it early and approach it adequately to avoid irreversible negative prejudice.
- | Trivastal (piribedil) / Servier
Journal: Studying the suitability of hybrid micelle liquid chromatography for estimating the lipophilicity of some partial dopamine agonists used to attain the reward circuit. (Pubmed Central) - Jun 5, 2021
Furthermore, the effect of the pH and the column temperature in HMLC on the practical log P values was studied. To verify its suitability for experimental measurement of log P , HMLC was subjected to full validation according to the United States Pharmacopeia.
- || Trivastal (piribedil) / Servier
Retrospective data, Review, Journal: The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis. (Pubmed Central) - Apr 10, 2021
To verify its suitability for experimental measurement of log P , HMLC was subjected to full validation according to the United States Pharmacopeia. No significant differences were found for pramipexole versus piribedil in the UPDRS II/III scores from baseline in early PD, with similar safety profiles.
- || Trivastal (piribedil) / Servier
Clinical, Journal: Pathological gambling in a patient on piribedil: A case report. (Pubmed Central) - Feb 24, 2021
This case further emphasizes the importance of monitoring and controlling Parkinson symptoms after drug reduction or withdrawal. Anticipation of this risk strengthens the significance of detailed medical history-taking and targeted clinical management.
- || Trivastal (piribedil) / Servier
Clinical, Journal: Association of Multiple Dopamine D3 Receptor Gene 3'UTR Polymorphisms with Susceptibility to Parkinson's Disease and Clinical Efficacy of Piribedil Therapy. (Pubmed Central) - Jan 29, 2021
PD patients were treated with piribedil sustained-release tablets (50 mg) combined with levodopa and benserazide hydrochloride tablets, three times daily (patients with first-diagnosed PD were only administrated with piribedil sustained-release tablets) for 3 months. The 3'UTR rs76126170, rs9868039, and rs9817063 SNPs of the DRD3 gene are associated with PD susceptibility and the clinical efficacy of piribedil treatment.
- | Trivastal (piribedil) / Servier
Journal: Mild cognitive impairment: modern aspects of diagnostics and therapy (Pubmed Central) - Dec 28, 2020
The mechanisms of action of the drug are analyzed, data from the main clinical studies of the efficacy and safety of piribedil are presented: the positive effect of the drug on cognitive functions has been shown in more than 10 international clinical trials including about 7000 patients and in a number of post-marketing works performed on the Russian population of patients. Piribedil is successfully used for various types of cognitive disorders, both neurodegenerative and vascular, of mild to moderate severity.
- || Retrospective data, Review, Journal: Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials. (Pubmed Central) - Apr 22, 2020
The currently available evidence does not allow for formulating recommendations for the use of prodopaminergic agents for the treatment of negative symptoms. Nevertheless, the observed improvement in studies defining a minimum threshold for negative symptom severity in the absence of an increase in positive symptoms clearly supports further research on these agents.
- Trivastal (piribedil) / Servier
[VIRTUAL] Novel mutation in DJ-1 (PARK7) gene in patients with Parkinson’s disease (Room: Screen A4) - Apr 9, 2020 - Abstract #EAN2020EAN_2082;
These 2 patients carrying exon 1 duplication in DJ-1 gene are characterized by a mild disease course with slow progression of symptoms, tremor-dominant phenotype and good response to L-dopa treatment. We suggest that partial dysfunction of DJ-1 protein in heterozygous carriers of mutations leads to the development of the more benign form of PD.
- | Trivastal (piribedil) / Servier
Journal: Homoleptic Bis(trimethylsilyl)amides of Yttrium Complexes Catalyzed Hydroboration Reduction of Amides to Amines. (Pubmed Central) - Feb 6, 2020
This transformation has also been nicely applied to the synthesis of indoles and piribedil. Detailed isotopic labeling experiments, control experiments, and kinetic studies provided cumulative evidence to elucidate the reaction mechanism.
- | memantine / Generic mfg.
Journal: Small arms fire-like noise: Effects on hearing loss, gap detection and the influence of preventive treatment. (Pubmed Central) - Jan 4, 2020
As in the previous study, piribedil, memantine, and ACEMg treatment significantly reduced the noise-induced loss of ribbons, such that it was no longer significantly different from normal. However, it did not prevent development of the reduced gap detection indication of tinnitus in all treated noise exposed rats, reducing the incidence but not reaching significance.
- Comtan (entacapone) / Novartis, Orion
An unusual cause of rhabdomyolysis in the patients with Parkinson’s disease: A report of two cases (Agora 2 West, Level 2) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_829;
Excessive dopaminergic administration was a major cause [table1]. Prompt recognition and treatment are recommended for favorable outcome.
- | Trivastal (piribedil) / Servier
Journal: Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. (Pubmed Central) - Sep 11, 2019
Furthermore, both the Piribedil treatment and MLL1 depletion sensitized the MLL-r cells to doxorubicin-induced apoptosis. Our study support the hypothesis that Piribedil could serve as a new drug for the treatment of MLL-r AML and provide new insight for further optimization of targeting MLL1 HMT activity.
- | Trivastal (piribedil) / Servier, Permax (pergolide) / Eli Lilly
Clinical, Journal: A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions. (Pubmed Central) - May 31, 2019
In a D-Gα versus D-Gα screening, we retrieved five agonists that are currently being used in antiparkinsonian medications. We determined that in this assay, piribedil and pergolide are full agonists for the recruitment of Gα but are partial agonists for Gα, that the agonist activity of ropinirole is biased in favor of Gα recruitment, and that the agonist activity of apomorphine is biased for Gα We proposed that this newly developed assay could be used to develop molecules that selectively modulate a particular G protein pathway.
- | SCH-23390 / Boehringer Ingelheim
Journal: Dopaminergic mechanisms in periaqueductal gray-mediated antinociception. (Pubmed Central) - May 30, 2019
A selective D2-like receptor agonist (piribedil, 6 and 12 μg into the PAG) induced antinociception in the mechanical paw-withdrawal test, but not in the tail-flick test...These findings suggest that µ-opioid antinociception from the PAG depends on dopamine acting on both D1-like and D2-like receptors. Selective activation of PAG D2-like receptors induces antinociception mediated by supraspinal mechanisms dependent on inhibition of GABAA and activation of opioid neurotransmission.